Soliris

 

Topic mentions per year

Topic mentions per year

2006-2017
0246820062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal… (More)
Is this relevant?
2011
2011
A 34-year-old female recipient of a simultaneous pancreas-kidney transplant presented 7 days posttransplant with acute renal… (More)
Is this relevant?
2011
2011
 
Is this relevant?
2010
2010
To the editor: A week has passed since my last account, and I thought I might take some time to fill you all in. Saturday, two… (More)
Is this relevant?
2010
2010
Expenditure under the Community Drugs Schemes exceeded € 1.9 billion in 2008, a five fold increase over the decade 1998 – 2008… (More)
Is this relevant?
2008
2008
On March 16, 2007, eculizumab (Soliris; Alexion Pharmaceuticals, Inc. Cheshire, CT), a humanized monoclonal antibody that binds… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
Biologics have established a high profile along the whole research pipeline, accounting for four out of ten preclinical… (More)
Is this relevant?